Paul O’Brien, Ph.D.
Paul O’Brien, Ph.D. is a Director in Patient Square Public Opportunities at Patient Square Capital. Prior to joining Patient Square, Dr. O’Brien was an Associate Director on the M&A team at BridgeBio Pharma, where he evaluated clinical and commercial-stage health care opportunities with a focus on therapeutics. Earlier in his career, Dr. O’Brien held positions at Point72, Regeneron Pharmaceuticals, and Piper Sandler.
Dr. O’Brien holds a Ph.D. in Biochemistry and Molecular Biophysics from Columbia University, and an M.S. in Biotechnology and B.S.E. in Chemical and Biomolecular Engineering from the University of Pennsylvania.